Delcath Systems (DCTH) announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating Hepzato in combination with standard of care treatment for liver-dominant metastatic colorectal cancer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Updates Bylaws for Governance Efficiency
- Delcath Systems’ HEPZATO Drives Strong Growth and Expansion, Justifying Buy Rating
- Delcath Systems price target raised to $31 from $29 at H.C. Wainwright
- Delcath Systems Reports Strong Q2 2025 Results
- Delcath Systems Reports Strong Q2 Growth Amid Challenges